Frontiers in Oncology最新文献

{"title":"Innovative applications and future trends of multiparametric PET in the assessment of immunotherapy efficacy.","authors":"Tingting Qiao, Zhaoping Cheng, Yanhua Duan","doi":"10.3389/fonc.2024.1530507","DOIUrl":"https://doi.org/10.3389/fonc.2024.1530507","url":null,"abstract":"<p><strong>Background: </strong>The integration of multiparametric PET (Positron Emission Tomography.) imaging and multi-omics data has demonstrated significant clinical potential in predicting the efficacy of cancer immunotherapies. However, the specific predictive power and underlying mechanisms remain unclear.</p><p><strong>Objective: </strong>This review systematically evaluates the application of multiparametric PET imaging metrics (e.g., SUVmax [Maximum Standardized Uptake Value], MTV [Metabolic Tumor Volume], and TLG [Total Lesion Glycolysis]) in predicting the efficacy of immunotherapies, including PD-1/PD-L1 inhibitors and CAR-T therapy, and explores their potential role in improving predictive accuracy when integrated with multi-omics data.</p><p><strong>Methods: </strong>A systematic search of PubMed, Embase, and Web of Science databases identified studies evaluating the efficacy of immunotherapy using longitudinal PET/CT data and RECIST or iRECIST criteria. Only original prospective or retrospective studies were included for analysis. Review articles and meta-analyses were consulted for additional references but excluded from quantitative analysis. Studies lacking standardized efficacy evaluations were excluded to ensure data integrity and quality.</p><p><strong>Results: </strong>Multiparametric PET imaging metrics exhibited high predictive capability for efficacy across various immunotherapies. Metabolic parameters such as SUVmax, MTV, and TLG were significantly correlated with treatment response rates, progression-free survival (PFS), and overall survival (OS). The integration of multi-omics data (including genomics and proteomics) with PET imaging enhanced the sensitivity and accuracy of efficacy prediction. Through integrated analysis, PET metabolic parameters demonstrated potential in predicting immune therapy response patterns, such as pseudo-progression and hyper-progression.</p><p><strong>Conclusion: </strong>The integration of multiparametric PET imaging and multi-omics data holds broad potential for predicting the efficacy of immunotherapies and may support the development of personalized treatment strategies. Future validation using large-scale, multicenter datasets is needed to further advance precision medicine in cancer immunotherapy.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1530507"},"PeriodicalIF":3.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repeatability, reproducibility, and the effects of radiotherapy on radiomic features of lowfield MR-LINAC images of the prostate.","authors":"Parker Anderson, Nesrin Dogan, John Chetley Ford, Kyle Padgett, Garrett Simpson, Radka Stoyanova, Matthew Charles Abramowitz, Alan Dal Pra, Rodrigo Delgadillo","doi":"10.3389/fonc.2024.1408752","DOIUrl":"https://doi.org/10.3389/fonc.2024.1408752","url":null,"abstract":"<p><p>Definitive radiotherapy (RT) has been shown to be a successful method of treating prostate cancer (PCa) patients. Through radiomics, a quantitative analysis of medical images, it is possible to adapt treatment early on, which may prevent or mitigate future adverse events. During RT of PCa, low-field magnetic resonance (MR) images, taken with a LINAC onboard imaging system in a process known as magnetic resonance-guided radiotherapy (MRgRT), are used to improve treatment accuracy via superior setup compared to x-ray methods. This work investigated baseline repeatability of radiomic features (RFs) by comparing planning MR images (pMR) with first-fraction setup images (FX1) taken with onboard MRI. The changes in RFs following RT were also looked at with the use of last-fraction setup images (FX5). Earlier research has investigated the use of planning images from cone beam CT (CBCT), but to our knowledge no research has previously shown the relationship with onboard MRI. The correlation between FX1 images and 3T diagnostic MR (dT2) images was also studied. Forty-three first and second order radiomic features extracted from these images were compared by calculating Lin's concordance correlation coefficient (with Benjamini-Hochberg correction for multiple comparisons) between the modalities. FX1 and pMR images were correlated (p<0.05) for all but one RF. 12 RFs correlated between pMR and dT2 images. There was a noticeable change in correlation values for RFs when looking at FX1 and FX5 images, with only 15 correlating significantly. The change in correlation values between pMR and FX5 images was comparable to that between FX1 and FX5 images, with 33 features having a CCC value deviation of less than 0.1. These results demonstrate that RF features are repeatable across different images of the same modality without treatment intervention. This study has also shown a noticeable, reproducible change in RFs as RT goes on. Reproducibility of RFs between different modalities was not strong. This study demonstrated that we can reliably use onboard MRI to observe day-to-day feature changes as a result of RT.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1408752"},"PeriodicalIF":3.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Short-course hypofractionated radiation therapy combined with immune checkpoint inhibitors for the treatment of advanced ovarian mucinous cystadenocarcinoma.","authors":"Xinan Wan, Mingxing Fang, Le Yuan, Hang Zhang, Dan Wang","doi":"10.3389/fonc.2025.1430474","DOIUrl":"https://doi.org/10.3389/fonc.2025.1430474","url":null,"abstract":"<p><strong>Background: </strong>Ovarian mucinous cystadenocarcinoma is a rare subtype of ovarian epithelial carcinoma that is resistant to platinum-based chemotherapy and has a poor prognosis, and there is no standard treatment plan for patients for whom multiline treatment has failed.</p><p><strong>Case presentation: </strong>oma with FIGO stage IVB disease who was sequentially treated with paclitaxel liposomes+carboplatin, 5-Fu+CF+oxaliplatin, capecitabine+oxaliplatin, bevacizumab+FOLFOX4, S-1, and bevacizumab+oxaliplatin+raltitrexed chemotherapy. After the progression of the disease, a combination of short-course hypofractionated radiation therapy and immune checkpoint inhibitors was used. The radiotherapy target area was the metastatic lymph nodes in the right posterior part of the hepatic artery, with a radiation dose of 30 Gy/10 F. Camrelizumab, an immune checkpoint inhibitor, was administered intravenously every three weeks at a dose of 200 mg each time. The therapeutic effect was significant, with CA125 levels within the normal range. Metastatic lymph nodes disappeared from the abdominal cavity. The therapeutic effect achieved a complete response (CR). Currently, CA125 levels are within the normal range, and abdominal CT reveals no tumor recurrence or metastasis. The duration of response (DoR) reached over four years.</p><p><strong>Conclusion: </strong>Ovarian mucinous cystadenocarcinoma is a rare tumor with poor treatment efficacy and poor prognosis. Short-course hypofractionated radiation therapy combined with PD-1 inhibitors may be an effective and safe treatment strategy.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1430474"},"PeriodicalIF":3.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-positive gastric cancer: an extremely malignant subtype of gastric cancer with high serum alpha-fetoprotein and carcinoembryonic antigen concentrations.","authors":"Weixun Xie, Chengyu Hu, Hongming Liu, Zelai Wu, Bixian Luo, Xiaoying Wu, Chuanlei Tuo, Ziyin Deng, Han Liang, Yong Liu, Weihua Gong","doi":"10.3389/fonc.2024.1514069","DOIUrl":"https://doi.org/10.3389/fonc.2024.1514069","url":null,"abstract":"<p><strong>Background: </strong>Alpha-fetoprotein-producing gastric cancer (AFPGC) is a highly malignant subtype of gastric cancer, but solely alpha-fetoprotein may fail to accurately predict the prognosis. Although the utilization of multi tumor markers could improve stratified patient management, such research in AFPGC is still blank. This study seeks to evaluate whether combining multiple tumor markers can enhance risk stratification and identify AFPGC subtypes with poor prognosis.</p><p><strong>Methods: </strong>We first screened for patients with elevated serum CEA levels within the AFPGC cohort and evaluated their prognosis. Tumor characteristics and overall health conditions were analyzed to identify factors contributing to CEA elevation. Finally, the treatment responses of this group to different treatment modalities were also reviewed.</p><p><strong>Results: </strong>Approximately 45% of gastric cancer patients with elevated serum AFP also show increased CEA levels, classifying them as the dual-positive gastric cancer (DPGC) subgroup. These patients exhibit significantly shorter overall survival, heightened metastasis risk, and are more susceptible to systemic inflammation, immune response dysregulation, malnutrition, and cancer-related thrombosis. The elevation in serum CEA levels may indicate gastric cancer liver metastasis and increased neutrophils. While surgery is optimal for AFPGC, DPGC patients benefit significantly from immunotherapy combined with chemotherapy.</p><p><strong>Conclusions: </strong>In AFPGC, combining serum AFP and CEA offers a more accurate prognosis. The poor prognosis in DPGC may be associated with aggressive local properties and systemic complications. Liver metastases and increased neutrophils are associated with increased serum CEA in AFPGC. Immunochemotherapy is a viable option for DPGC patients who cannot undergo surgery.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1514069"},"PeriodicalIF":3.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solitary fibular metastasis from lung adenocarcinoma with gene mutation: a case report.","authors":"Jiechen Chen, Ahmad Alkhatatbeh, Yinbing Lin, Xiaolin Lu, Bin Chen, Hongjiang Chen, Xiaohui Lu, Hansheng Wu, Jun Hu","doi":"10.3389/fonc.2025.1490271","DOIUrl":"https://doi.org/10.3389/fonc.2025.1490271","url":null,"abstract":"<p><p>Solitary fibular metastasis from lung adenocarcinoma is exceedingly rare, with only five documented cases. This report presents a 40-year-old non-smoking Asian male who initially presented with painful swelling in the right knee. Imaging revealed bony destruction of the right fibular head, and further investigations with chest CT, PET/C, pathologic biopsy and genetic testing identified a primary lung adenocarcinoma with EGFR exon 19 deletion mutation. The patient was treated with Osimertinib, resulting in significant tumor reduction. This was followed by thoracoscopic lobectomy and systematic lymph node dissection, and local radiotherapy for the fibular metastasis. The patient experienced complete pain relief and showed no recurrence or metastasis over a 26-month follow-up. This case highlights the diagnostic challenge posed by atypical presentations of metastasis and underscores the importance of comprehensive evaluation, adherence to treatment guidelines, and a multidisciplinary approach in managing oncological patients. The successful outcome in this young patient emphasizes the effectiveness of personalized treatment strategies in optimizing patient prognosis, offering valuable insights for similar clinical scenarios.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1490271"},"PeriodicalIF":3.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitochondrial abnormalities as a target of intervention in acute myeloid leukemia.","authors":"Elissa Tjahjono, Megan R Daneman, Bernadetta Meika, Alexey V Revtovich, Natalia V Kirienko","doi":"10.3389/fonc.2024.1532857","DOIUrl":"https://doi.org/10.3389/fonc.2024.1532857","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is an aggressive hematological malignancy; it is the most common acute leukemia in adults. AML prognosis is often poor, and relapse often occurs after initial remission. Recurrent genetic abnormalities underlying this disease and the presence of leukemic stem cells complicate disease treatment. However, the complex metabolic reprogramming that enables the unrestrained cell growth seen in these cells may also be their Achilles' heel. In these cells, mitophagy operates as a double-edged sword. On one hand, it provides a source of building blocks for further cell division and serves as a method for removing damaged organelles, promoting cell survival. However, the profound metabolic changes to mitochondria also render these organelles more sensitive to damage and place them precariously close to excess mitophagic activation. This review discusses the dual role mitophagy plays in AML survival, the importance of targeting mitophagy to treat AML, and current progress in the area. The discovery and mechanism of action of multiple compounds that were used to inhibit or stimulate mitophagy and their effects on AML survival are also described. Further, we explore the combination strategy of mitophagy-targeting compounds with existing and/or novel chemotherapeutics to eradicate AML and discuss strategies to uncover new drug targets and novel mitochondria-targeting drugs.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1532857"},"PeriodicalIF":3.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the role of SYNGR4 in breast cancer development: a novel target for immunotherapy.","authors":"Jie Ma, Hongtao Wang, Zhengwei Gui, Yuanrong Yang","doi":"10.3389/fonc.2024.1490073","DOIUrl":"https://doi.org/10.3389/fonc.2024.1490073","url":null,"abstract":"<p><strong>Introduction: </strong>SYNGR4 is considered to be one of the causative genes for amyotrophic lateral sclerosis, but its role in breast cancer development has not been revealed.</p><p><strong>Methods: </strong>The expression of SYNGR4 in a variety of malignancies including breast cancer was analyzed using Genotype Tissue Expression (GTEx) and the Cancer Genome Atlas (TCGA) databases and verified by specimens collected from our center. The effect of SYNGR4 on breast cancer prognosis was analyzed using bioinformatics and possible pathways by which this molecule affects breast cancer prognosis were explored. The effect of SYNGR4 on immune infiltration of breast cancer was analyzed using GSVA, and the effects of SYNGR4 on breast cancer proliferation, migration, and tumor-associated macrophage polarization in cancer foci were verified by cellular and animal experiments, respectively.</p><p><strong>Results: </strong>SYNGR4 is highly expressed in a variety of malignant tumors, including breast cancer, and affects the prognosis of breast cancer patients. This may be a volatile effect through Organelle fission, chromosome segregation, nuclear division, etc. SYNGR4 overexpression affects breast cancer proliferation, migration, and tumor immune infiltration, and promotes breast cancer tumor-associated macrophage polarization toward M2.</p><p><strong>Discussion: </strong>SYNGR4 overexpression can affect the prognosis of breast cancer patients by promoting M2 polarization of tumor-associated macrophages in breast cancer, and this molecule may be a novel target for breast cancer immunotherapy.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1490073"},"PeriodicalIF":3.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyanoacrylate glue in breast surgery: the GLUBREAST Trial.","authors":"Emanuela Esposito, Claudio Siani, Ivana Donzelli, Anna Crispo, Sergio Coluccia, Piergiacomo Di Gennaro, Assunta Luongo, Franca Avino, Alfredo Fucito, Ugo Marone, Maria Teresa Melucci, Ruggero Saponara, Raimondo di Giacomo","doi":"10.3389/fonc.2024.1473157","DOIUrl":"https://doi.org/10.3389/fonc.2024.1473157","url":null,"abstract":"<p><strong>Introduction: </strong>In 2018, the National Cancer Institute of Naples has launched the GLUBREAST Trial to verify the efficacy of cyanoacrylate sealing glue to prevent or reduce seroma after axillary dissection in breast surgery. The glue is a synthetic sealant (N-Butyl-2-CyanoAcrylate+Metacryloxisulfolane) biocompatible, CE approved for internal human uses and surgical procedures. The assumed mechanism of action in breast surgery is that the glue would create a seal coating in the operative field to occlude lymphatic leaks and limit seroma formation.</p><p><strong>Materials and methods: </strong>The trial included 180 patients scheduled for breast-conserving surgery or for radical modified mastectomy without reconstruction. Out of 180 patients, 91 were randomized to receive suction drain and sealant glue after axillary dissection (Experimental Arm), whereas 89 patients (Control Arm) received suction drain without glue.</p><p><strong>Statistics: </strong>A multivariable mixed effect model on presence of liquid drained and volume drained was calculated. Stratified models by visits were performed.</p><p><strong>Results: </strong>The trial ended in June 2022. Older age was associated with a higher volume of seroma drained per day (β 0.30; 95% CI: 0.00-0.60). A 5-U increase in body mass index was associated with higher daily drained seroma volume in patients who underwent breast-conserving surgery (β 5.0; 95% CI: 0.62-9.4), but not in patients who underwent mastectomy (β 2.5; 95% CI: -3.6-8.6). We did not find statistically significant differences in presence of liquid drained and volume drained among the study groups. An advantage for the Experimental Arm was observed from third and fourth to fifth outpatient visits without reaching a statistical significance (p=0.069 and p=0.072, respectively); so far, 5% of patients in the Experimental Group had clinical benefit from the glue.</p><p><strong>Conclusions: </strong>The vast majority of data in the literature come from case series, and surgeons need a higher level of evidence to drive surgical decision-making and choose proper devices to increase patient quality of life. The GLUBREAST randomized trial tested the efficacy of cyanoacrylate sealing glue to prevent postoperative seroma in breast surgery. Although only a small number of patients benefited from sealant application, we regret to say this trial has some limitation, i.e., the prolonged presence of suction drain. Further research is warranted to better clarify the benefit of cyanoacrylate glue in breast surgery.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1473157"},"PeriodicalIF":3.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility study.","authors":"Renxian Xie, Hongxin Huang, Qingxin Cai, Jiayang Lu, Tong Chen, Keyan Xie, Jianzhou Chen, Chuangzhen Chen","doi":"10.3389/fonc.2024.1445558","DOIUrl":"https://doi.org/10.3389/fonc.2024.1445558","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy can improve the survival rates of patients with glioma; meanwhile, impaired cognitive functions have been brought to the forefront with the offending organ, the radiosensitive hippocampus. This study aimed to assess the feasibility of hippocampus-sparing volumetric-modulated arc therapy (HS VMAT) in patients with World Health Organization (WHO) grade II glioma.</p><p><strong>Methods: </strong>HS VMAT plans and non-hippocampus-sparing volumetric-modulated arc therapy (NHS VMAT) plans were generated using a computed tomography (CT) dataset of 10 patients who underwent postoperative radiotherapy. The dose volume histogram (DVH), homogeneity index (HI), conformity index (CI), and irradiated dose of the hippocampus and other organs at risk (OARs) were analyzed.</p><p><strong>Results: </strong>No significant differences were observed in HI and CI between the two plans. Regarding the protection of OARs, HS VMAT plans were equally capable and even lowered the radiation dosages to the brainstem (35.56 vs. 41.74 Gy, p = 0.017) and spinal cord (1.34 vs. 1.43 Gy, p = 0.006). Notably, HS VMAT plans markedly decreased doses to the ipsilateral hippocampus and the contralateral hippocampus, demonstrating its efficacy in hippocampal dose reduction.</p><p><strong>Conclusion: </strong>The HS VMAT plan can be used to efficiently lower the dosage delivered to the hippocampus and may, to some extent, help lessen the risk of cognitive damage. The encouraging results of our study need to be further validated by clinical trials to confirm the benefits of the HS VMAT plans in preserving cognitive functions in patients with glioma.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1445558"},"PeriodicalIF":3.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical analysis of molecular typing of 146 cases of endometrial carcinoma.","authors":"Bo Zhang, Dan Zhou, Shuo Zhang, Jinbowen Yan, Qingwei Meng, Qiubo Lv","doi":"10.3389/fonc.2024.1482817","DOIUrl":"https://doi.org/10.3389/fonc.2024.1482817","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the application of TCGA molecular typing in endometrial carcinoma, compare the relationship between molecular typing and clinicopathologic features, and provide a new idea for individual treatment of patients.</p><p><strong>Methods: </strong>A total of 146 EC patients who underwent surgical treatment and TCGA molecular typing in Beijing Hospital from December 2019 to March 2023 were collected. The clinicopathologic features, immunohistochemistry, and prognosis of the four TCGA molecular types were analyzed retrospectively.</p><p><strong>Result: </strong>Among the 146 patients with endometrial cancer (EC), 8 patients (5.5%) exhibited the POLE hypermutant type, 29 patients (19.9%) displayed the MSI-H type, 94 patients (64.4%) presented the low copy-number type, and 15 patients (10.3%) manifested the high copy-number type. A comparative analysis of the four TCGA types and age yielded statistically significant results (p = 0.012). Notably, significant associations were observed between menopausal status, the expression of ER, PR, and the four TCGA types. However, no significant difference was observed in CA125 levels before surgery among the four TCGA types (p = 0.587). There were significant differences observed among the four TCGA types and pathological types, pathological grades, FIGO stage, lymph node metastasis, and LVSI. The progression-free survival (PFS) rates of patients with POLE hypermutation, MSI-H type, CNL type, and CNH type were 100%, 100%, 93.62%, and 73.3%, respectively. There was a statistically significant difference between the four groups(p=0.006). POLE mutant and MSI-H type patients have higher PFS, while high copy type patients have the lowest.</p><p><strong>Conclusions: </strong>TCGA molecular typing has feasibility and application value in the clinical application of endometrial cancer, and has a certain predictive effect on the prognosis of EC patients. It has a certain guiding significance for the individual treatment of patients with endometrial cancer.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1482817"},"PeriodicalIF":3.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}